CA2490142A1 - Liquid dosage forms of proton pump inhibitors - Google Patents
Liquid dosage forms of proton pump inhibitors Download PDFInfo
- Publication number
- CA2490142A1 CA2490142A1 CA002490142A CA2490142A CA2490142A1 CA 2490142 A1 CA2490142 A1 CA 2490142A1 CA 002490142 A CA002490142 A CA 002490142A CA 2490142 A CA2490142 A CA 2490142A CA 2490142 A1 CA2490142 A1 CA 2490142A1
- Authority
- CA
- Canada
- Prior art keywords
- micro
- granules
- liquid
- viscosity
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19023902A | 2002-07-03 | 2002-07-03 | |
US10/190,239 | 2002-07-03 | ||
PCT/US2003/020946 WO2004004690A1 (en) | 2002-07-03 | 2003-07-02 | Liquid dosage forms of proton pump inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2490142A1 true CA2490142A1 (en) | 2004-01-15 |
Family
ID=30114048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002490142A Abandoned CA2490142A1 (en) | 2002-07-03 | 2003-07-02 | Liquid dosage forms of proton pump inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1572151A1 (es) |
JP (2) | JP5148813B2 (es) |
CA (1) | CA2490142A1 (es) |
MX (1) | MXPA05000301A (es) |
WO (1) | WO2004004690A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9901551B2 (en) * | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
MX2013004364A (es) | 2010-10-19 | 2013-07-02 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
WO2013058996A1 (en) * | 2011-10-19 | 2013-04-25 | R.P. Scherer Technologies, Llc | Two phase pharmaceutical delivery system |
GB2535130B (en) * | 2014-09-29 | 2020-09-02 | Veriton Pharma Ltd | A Suspension |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
GB202116644D0 (en) | 2021-11-18 | 2022-01-05 | Innovate Pharmaceuticals Ltd | Liquid composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9301489D0 (sv) * | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
WO1999029320A1 (en) * | 1997-12-08 | 1999-06-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel administration form comprising an acid-labile active compound |
DE19925710C2 (de) * | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
KR20030059318A (ko) * | 2000-12-07 | 2003-07-07 | 알타나 파마 아게 | 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제 |
-
2003
- 2003-07-02 JP JP2004519828A patent/JP5148813B2/ja not_active Expired - Fee Related
- 2003-07-02 MX MXPA05000301A patent/MXPA05000301A/es active IP Right Grant
- 2003-07-02 WO PCT/US2003/020946 patent/WO2004004690A1/en active Application Filing
- 2003-07-02 CA CA002490142A patent/CA2490142A1/en not_active Abandoned
- 2003-07-02 EP EP03763155A patent/EP1572151A1/en not_active Withdrawn
-
2012
- 2012-07-26 JP JP2012165900A patent/JP2013028603A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2005535661A (ja) | 2005-11-24 |
JP2013028603A (ja) | 2013-02-07 |
EP1572151A1 (en) | 2005-09-14 |
JP5148813B2 (ja) | 2013-02-20 |
WO2004004690A1 (en) | 2004-01-15 |
MXPA05000301A (es) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080274200A1 (en) | Dose titratable liquid dosage forms of acid labile drugs | |
JP6209237B2 (ja) | 酸不安定性薬物の液体剤形 | |
US20080292710A1 (en) | Liquid Dosage Forms Of Acid Labile Drugs | |
ES2389844T3 (es) | Forma de dosificación sólida que comprende inhibidor de la bomba de protones, y suspensión obtenida de ella | |
ES2399898T3 (es) | Composiciones farmacéuticas de sabor enmascarado preparadas por coacervación | |
US20100004291A1 (en) | Liquid dosage forms of non-enterically coated acid-labile drugs | |
KR20040099265A (ko) | 신규의 치환 벤즈이미다졸 제형 및 그 사용방법 | |
KR20040047771A (ko) | 신규의 치환 벤즈이미다졸 제형 및 그 사용방법 | |
JP2011144168A (ja) | 非腸溶性酸不安定性薬物の液体剤形 | |
KR20020029668A (ko) | 풍미 차단된 약제학적 액상 제제 | |
JP2013028603A (ja) | プロトンポンプ阻害剤の液体剤形 | |
BR112021016421A2 (pt) | Minimização de aglomeração, aeração e preservação do revestimento de composições farmacêuticas que compreendem ibuprofeno | |
EP3733167A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
US20150050336A1 (en) | Taste Masking System For Non-Plasticizing Drugs | |
Johnson et al. | Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages | |
JP2006522089A (ja) | 被覆オキサゾリジノン粒子のための味のマスキング用ビヒクル | |
JPH0440327B2 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |
Effective date: 20140429 |